REL proto-oncogene (c-Rel) (Internal Region) Peptide
c-Rel
Reactivité: Humain
Hôte: Synthetic
BP, BI
-
- Antigène Tous les produits c-Rel
- c-Rel (REL proto-oncogene (c-Rel))
- Type de proteíne
- Synthetic
- Protein Region
- Internal Region
- Origine
- Humain
-
Source
- Synthetic
- Application
- Blocking Peptide (BP), BioImaging (BI)
- Attributs du produit
- REL peptide is a synthetic peptide corresponding to the internal region of REL.
-
-
- Indications d'application
- REL Peptide is used for blocking the activity of REL antibody. The best starting ratio would be 1:1 (which means molar excess of peptide relative to antibody when identical volumes are mixed). Mix equal volume of peptide and antibody at the required dilution and leave at ambient temperature for 20 minutes. Then incubate and develop in parallel two blots: one with the antibody and one with the antibody which has been pre-absorbed with the provided peptide.
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- REL peptide is supplied as 100 μg of dried peptide. When the peptide is reconstituted in 200 ?L water, the concentration will be 0.5 mg/mL.
- Conseil sur la manipulation
- When reconstituted minimize freezing and thawing.
- Stock
- -20 °C
- Stockage commentaire
- Store at -20 °C.
-
- Antigène
- c-Rel (REL proto-oncogene (c-Rel))
- Synonymes
- C-Rel Peptide, c-Rel Peptide, NFkB Peptide, c-rel Peptide, zgc:100833 Peptide, Xrel2 Peptide, Xrel3 Peptide, rel Peptide, rel-A Peptide, rel2 Peptide, rel3 Peptide, v-rel Peptide, xrel Peptide, REL proto-oncogene, NF-kB subunit Peptide, reticuloendotheliosis oncogene Peptide, RELA proto-oncogene, NF-kB subunit Peptide, v-rel avian reticuloendotheliosis viral oncogene homolog Peptide, v-rel avian reticuloendotheliosis viral oncogene homolog L homeolog Peptide, ribonuclease A family member 2 pseudogene Peptide, REL Peptide, Rel Peptide, Rela Peptide, rel Peptide, rel.L Peptide, ECRP Peptide
- ID gène
- 5966
- NCBI Accession
- NP_005682, NP_064693
- UniProt
- Q04864
-
Vous êtes ici:
